Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Revenue of Aptinyx Inc. (APTX)
Revenue in 2022 (TTM): $
According to Aptinyx Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Aptinyx Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $ | $ | $-61,708,000 | $-64,849,000 | $-64,112,000 |
| 2021 | $1000 K | $1000 K | $ | $-74,886,000 | $-74,360,000 |
| 2020 | $1.56 M | $1.56 M | $-50,765,000 | $-50,053,000 | $-49,632,000 |
| 2019 | $3.67 M | $3.67 M | $-59,613,000 | $-57,410,000 | $-56,955,000 |
| 2018 | $6.57 M | $6.57 M | $-54,888,000 | $-53,281,000 | $-53,281,000 |
| 2017 | $4.96 M | $4.96 M | $-31,828,000 | $-32,068,000 | $-32,068,000 |
| 2016 | $9.79 M | $9.79 M | $-17,532,000 | $-15,478,000 | $-15,478,000 |